Vetter, a global leader in contract development and manufacturing (CDMO) for the biopharmaceutical sector, has announced that Managing Director Thomas Otto will retire at the end of 2025, concluding more than 35 years of service with the company.
Throughout his tenure, Thomas Otto has played a pivotal role in guiding Vetter’s sustainable growth and international development. Under his leadership, the company strengthened its partnerships with global biopharmaceutical firms and reinforced its reputation for delivering high-quality, life-enhancing medicines.
“Thomas Otto has decisively advanced our family business with his vision, innovative strength and great sense of responsibility,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board. “His contribution to Vetter’s development and internationalisation is outstanding and deserves the highest recognition. He was a reliable designer, initiator and bridge builder – both within the company and externally. On behalf of the Vetter family and the advisory board, I would like to thank him for his extraordinary commitment and lasting impact on our success story.”
Reflecting on his career, Thomas Otto shared, “I am grateful for the many years at Vetter and proud of what we have achieved together. I am extremely pleased that I was able to contribute to making the company strong and fit to take on the future. I wish my colleagues in the management team continued success in leading Vetter with competence and passion.”
Thomas Otto will continue to support the company in an advisory role, lending his extensive expertise to the planned development of a new production site in Germany.
Vetter has also implemented a proactive succession strategy. Early in 2025, long-standing executives Henryk Badack, Titus Ottinger, and Carsten Press were appointed to the Management Board as Managing Directors. With their deep knowledge of the company, its customers, and the industry, they are well-positioned to ensure continuity and reinforce trust with the owner family and Advisory Board.
As Vetter looks to the future, the company remains committed to its customers, employees, and partners, continuing to provide reliable, high-quality solutions that enable patients worldwide to access life-enhancing medicines.